title: [Conversion from a calcineurin inhibitor to a sirolimus-based                     therapy after renal transplantation - An update of existing                     recommendations].
authors: Medizinische Klinik I - Nephrologie, Klinikum Köln-Merheim, Universität Witten-Herdecke. wolfgang.arns@uni-koeln.de
authors: W
authors: W
authors: Arns
authors: K
authors: K
authors: Budde
authors: F
authors: F
authors: Eitner
authors: W
authors: W
authors: Gwinner
authors: C
authors: C
authors: Hugo
authors: K
authors: K
authors: Pressmar
authors: A
authors: A
authors: Weimann
authors: O
authors: O
authors: Witzke
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use; D065095:Calcineurin Inhibitors; D000075202:Contraindications; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D057915:Drug Substitution; D006084:Graft Rejection / Q000188:drug therapy / Q000276:immunology* / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007677:Kidney Function Tests; D016030:Kidney Transplantation / Q000276:immunology*; D009369:Neoplasms / Q000188:drug therapy; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D020123:Sirolimus / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000903:Antibiotics, Antineoplastic; D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D020123:Sirolimus